China Rheumatoid Arthritis Prescription Drug Sales Data 2006-2010
Draco Healthcare Consulting LLC, November 2011
The series of China Prescription Drug (CPD) sales reports have systemically analyzed Chinese prescription drug market, according to different therapeutic areas. All market estimates of drug utilization in China are based on hospital drug prescription and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.
Market shares from all major manufacturers including multinational and Chinese pharmaceutical companies and key products are analyzed systemically. The comprehensive prescription data in China will present you a clear picture of the competition landscape of Chinese drug market for each therapeutic area (such as cancer, hypertension, diabetes, to name a few) and the market potential for your company's product(s) that already marketed in China or if you are planning to bring your drugs to the China market.
This series of China CPD reports have been indispensable references for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug sales reports in China, this multi-client report provides significant savings and great cost/benefit.
All China Prescription Drug Sales Database provides the following information, annually:
- Annual national sales of individual therapeutic area 2006-2010
- Annual national sales from each of the top manufacturers in each therapeutic area 2006-2010
- Annual national sales and market shares for each of the top drugs in each therapeutic area 2006-2010
- Annual national sales of the top drugs by each of the competing manufacturers 2006-2010
- Names, packages, prices and manufacturers of brand and generic drugs in each therapeutic area 2010
- Drugs on the Basic Medical Insurance List in 2010
Products Mentioned:
- Glucosamine
- Cervus and Cucumis Polypeptide
- Flurbiprofen
- Celecoxib
- Leflunomide
- Diclofenac
- Qizheng Xiaotongtie
- Meloxicam
- Ibuprofen
- Nimesulide
- Parry Celebrex
- Lornoxicam
- Wanying Zitonggao
- Aceclofenac
- Diacerein
- Glucosamine potassium
- Gutongtie
- Ketoprofen
- Indomethacin
- Nabumetone
1. Historic annual drug sales of rheumatoid arthritis Drugs in the Chinese market (2006-2010)
2. Sales and market shares of top 20 manufacturers in the rheumatoid arthritis market in China (2006-2010)
3. Sales and market shares of top drugs in the rheumatoid arthritis market in China (2006-2010)
4. Sales and market shares of competitors for each top drug in the rheumatoid arthritis market in China (2006-2010)
5. List of Retail Prices for Rheumatoid Arthritis Drugs in China in 2010
6. List of drugs covered by the National Healthcare Basic Insurance, and coverage category in the rheumatoid arthritis market in China in 2010
- Harbin Yuheng
- Beijing Taide
- Shanxi Zhongyuanwei
- Pfizer
- Suzhou Changzheng Xinkai
- Tibet Qizheng
- Rotta Research Laboratorium S.p.A.
- Beijing Novartis
- Heilongjiang Jiangshi
- Zhejiang Haizheng
- Hong Kong Bright Future
- Boehringer Ingelheim
- Fujian Huitian
- Shanghai Johnson & Johnson
- Heilongjiang Dilong
- Tianjin Smith Kline
- Sichuan Yangtian
- Shanxi Kangbao
- Klinger
- Sichuan Xinsidun
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
